VEGFR-2 inhibitors increased overall cardiovascular events (RR 2.52) and hypertension (RR 3.17) but reduced thromboembolic events (RR 0.78) in solid tumor patients.
Does treatment with VEGFR-2 targeted inhibitors increase the risk of cardiovascular adverse events in patients with solid tumors?
VEGFR-2 targeted inhibitors significantly increase the risk of cardiovascular adverse events and hypertension in patients with solid tumors, highlighting the critical need for routine blood pressure monitoring during therapy.
Absolute Event Rate: 0% vs 0%
Abstract The efficacy of vascular endothelial growth factor receptor 2 (VEGFR 2)-targeted agents in the treatment of malignant tumors has been reported, but research on the related cardiovascular risks is limited. Therefore, we conducted a meta-analysis of randomized controlled trials to determine the risk of cardiovascular events, hypertension, thromboembolic events, pulmonary embolism, acute coronary syndrome, arrhythmias, and heart failure associated with VEGFR-2 targeted inhibitors in patients with solid tumors. We systematically searched PubMed, Web of Science Core Collection, Cochrane Library, and EMBASE for articles published until April 11, 2024. This study included 34 trials (n=11204 solid tumor patients). VEGFR-2 targeting agents increased the risk of overall cardiovascular events relative ratios (RR), 2.524 [95% confidence intervals (CI), 2.133–2.987; P=0.000] and hypertension (RR, 3.17 95%CI, 2.686–3.760; P=0.000), while reducing the risk of thrombotic events (RR, 0.783 95%CI, 0.621–0.988; P=0.039). The risk of acute coronary syndrome (RR, 1.015 95%CI, 0.568–1.814; P=0.959), arrhythmias (RR, 1.155 95%CI, 0.826–1.615; P=0.399), heart failure (RR, 1.641 95%CI, 0.816–3.302; P=0.165), or pulmonary embolism (RR, 0.786 95%CI, 0.542–1.138; P=0.201) did not increased. VEGFR 2-targeted agents can significantly increase the risk of total cardiovascular adverse events and hypertension. The risk of thromboembolic events associated with these drugs was significantly reduced, while the risk of heart failure, acute coronary syndrome, arrhythmia, and pulmonary embolism did not increase significantly. The study indicates the importance of blood pressure monitoring when using such drugs.
Feng Chen (Sat,) reported a other. VEGFR-2 inhibitors increased overall cardiovascular events (RR 2.52) and hypertension (RR 3.17) but reduced thromboembolic events (RR 0.78) in solid tumor patients.